Objective: To investigate the efficacy and safety of micro-transplantation in acute myeloid leukemia (AML).
Methods: The clinical data of 13 adult AML patients who received micro-transplantation as consolidation therapy from July 2014 to October 2019 was retrospectively analyzed, and the adverse reactions and efficacy of micro-transplantation were followed up.
Results: Eight patients received micro-transpantation were still in complete remission, 5 patients relapsed after micro-transplantation, 1 of them received umbilical cord blood micro-transplantation after remission by reinduction, and all of the 13 patients have survived till now. The median overall survival time was 13 months, and the median relapse-free survival time was 12 months. All 13 patients developed grade 2-4 hematological adverse reactions. The median recovery time of neutrophils and platesets was 13 (11-15) and 15 (13-17) days, respectively. None of the 13 patients developed acute or chronic graft versus host disease. Twelve patients suffered from different infections, however, there were no serious organ function injury complications happened.
Conclusion: The micro-transplomtation of HLA-incompatible stem cells derived from peripheral blood or umbilical and blood is an effective regimen for the consolidation therapy of AML, especially for the patients suffered from low and moderate risk of AML or the aged AML patients.
题目: 微移植巩固治疗对完全缓解后急性髓系白血病患者的疗效分析.
目的: 观察微移植在急性髓系白血病（AML）中的疗效与安全性.
方法: 回顾性分析2014年7月至2019年10月接受微移植作为巩固治疗的13例成人AML患者的临床资料，随访观察微移植治疗的不良反应与疗效.
结果: 13例微移植患者中有8例仍处于完全缓解状态，5例患者微移植后复发，其中1例再诱导缓解后行脐血微移植。目前13例均处于生存状态，中位总生存期为13个月，中位无复发生存期为12个月。13例患者均发生2-4级血液学不良反应；中性粒细胞中位恢复时间13（11-15）d，血小板中位恢复时间15（13-17）d。13例患者均未发生急慢性移植物抗宿主病；12例患者发生不同严重程度的感染，无严重脏器功能损伤.
结论: HLA不相合外周血和脐血来源的干细胞微移植是巩固治疗AML的有效方案，尤其对于低中危、老年AML患者疗效较显著.